The Action Potential Clamp Technique as a Tool for Risk Stratification of Sinus Bradycardia Due to Loss-of-Function Mutations in HCN4: An In Silico Exploration Based on In Vitro and In Vivo Data.

These days, in vitro functional analysis of gene variants is becoming increasingly important for risk stratification of cardiac ion channelopathies. So far, such risk stratification has been applied to , , and gene variants associated with Brugada syndrome and long QT syndrome types 1 and 2, respectively, but risk stratification of gene variants related to sick sinus syndrome has not yet been performed. is the gene responsible for the hyperpolarization-activated 'funny' current I, which is an important modulator of the spontaneous diastolic depolarization underlying the sinus node pacemaker activity. In the present study, we carried out a risk classification assay on those loss-of-function mutations in for which in vivo as well as in vitro data have been published. We used the in vitro data to compute the charge carried by I (Q) during the diastolic depolarization phase of a prerecorded human sinus node action potential waveform and assessed the extent to which this Q predicts (1) the beating rate of the comprehensive Fabbri-Severi model of a human sinus node cell with mutation-induced changes in I and (2) the heart rate observed in patients carrying the associated mutation in . The beating rate of the model cell showed a very strong correlation with Q from the simulated action potential clamp experiments (R = 0.95 under vagal tone). The clinically observed minimum or resting heart rates showed a strong correlation with Q (R = 0.73 and R = 0.71, respectively). While a translational perspective remains to be seen, we conclude that action potential clamp on transfected cells, without the need for further voltage clamp experiments and data analysis to determine individual biophysical parameters of I, is a promising tool for risk stratification of sinus bradycardia due to loss-of-function mutations in . In combination with an I blocker, this tool may also prove useful when applied to human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) obtained from mutation carriers and non-carriers.